Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Long-Term Safety Study of Lacosamide for Children with Epilepsy

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the long-term use of a medication called lacosamide in children with epilepsy. Epilepsy is a condition that affects the brain and causes repeated seizures. The medication being tested, lacosamide, is given in the form of a syrup and is taken orally. The purpose of this study is to learn if lacosamide is safe to take over a long period of time for children who have already participated in previous studies involving this medication.

Participants in this study will continue to take lacosamide syrup, with doses ranging from 2 milligrams per kilogram of body weight per day to 12 milligrams per kilogram per day. The study will monitor the participants over time to observe any side effects or adverse events that may occur while taking the medication. The study aims to ensure that the medication is safe and to determine the most suitable daily dose for long-term use.

The study is designed to follow participants who have completed earlier studies, ensuring they continue to receive treatment and monitoring. The researchers will collect information on any side effects, changes in health, and the overall effectiveness of the medication in managing epilepsy symptoms. This information will help in understanding the long-term safety and benefits of using lacosamide in children with epilepsy.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be asked to confirm that you have completed participation in one of the previous studies, either EP0034 or SP848. This is a requirement to ensure that you are eligible to participate in this follow-up study.

    You will also need to provide consent, which means agreeing to participate in the study after understanding all the details and what is expected of you.

  2. Step 2

    Medication administration

    You will be given a medication called lacosamide, which is a syrup taken by mouth. The dosage will be between 2 mg/kg/day and 12 mg/kg/day. The exact dose will be determined by the study team based on your specific needs.

    The medication is intended to be taken daily, and the study will monitor how you respond to this treatment over a long period.

  3. Step 3

    Monitoring and assessments

    Throughout the study, you will be regularly monitored to assess your response to the medication. This includes checking for any side effects or adverse reactions, which are called treatment-emergent adverse events (TEAEs).

    The study team will also track the daily dose you are taking and any changes in your condition.

  4. Step 4

    Completion of the study

    The study is expected to continue until August 31, 2025. During this time, you will continue to take the medication and attend regular check-ups as scheduled by the study team.

    At the end of the study, your overall health and response to the medication will be evaluated to determine the long-term safety and effectiveness of lacosamide for treating epilepsy.

Who can join the trial?

4 criteria

  • The participant can be a boy or girl.
  • The participant must be younger than 6 years old at the time of signing the consent form.
  • The participant must have completed participation in one of the previous studies: NCT01964560 (EP0034) or NCT00938912 (SP848).
  • The participant is expected to benefit from participation, according to the study doctor.

Who cannot join the trial?

6 criteria

  • Patients who have not completed the previous studies identified as NCT01964560 or NCT00938912 cannot participate.
  • Patients who are not within the age range specified for the study.
  • Patients who are not diagnosed with epilepsy.
  • Patients who are not able to take the medication in the form of an oral solution.
  • Patients who have any other medical condition that might interfere with the study.
  • Patients who are not able to follow the study procedures or instructions.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Lacosamide is a medication used in this clinical trial to help manage epilepsy in children. It is taken by mouth as a solution. The main goal of using lacosamide in this study is to see how well it works and how safe it is for long-term use in children who have already been treated with it in previous studies. Lacosamide helps to control seizures by affecting the way electrical signals in the brain are transmitted, which can help reduce the frequency and severity of seizures in people with epilepsy.

What is already known about the treatment

Lacosamide – Lacosamide is administered orally, typically in the form of a solution, and is used to treat epilepsy, a condition characterized by recurrent seizures. It is currently being studied in clinical trials to evaluate its long-term use in children who have previously participated in related studies. Lacosamide works by stabilizing electrical activity in the brain, which helps to prevent seizures. It belongs to a class of medications known as anticonvulsants, which are used to control seizures in various types of epilepsy.

Investigated diseases

Epilepsy – Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures. These seizures are episodes of disturbed brain activity that can cause changes in attention or behavior. The condition can affect people of all ages and may vary in severity and frequency. Seizures can manifest as brief lapses of attention, muscle spasms, or convulsions. The progression of epilepsy can involve changes in seizure patterns over time. It is a chronic condition that requires ongoing management.
Trial detailsLast updated 7 Oct 2026
Age0-17PhasePhase IIITrial ID2022-502639-21-00Protocol codeEP0151Estimated enrolment49 patientsSponsorUCB Biopharma

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.